Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Total Liabilities (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Total Liabilities for 7 consecutive years, with $17.3 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 2.26% to $17.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.3 million through Dec 2025, down 2.26% year-over-year, with the annual reading at $17.3 million for FY2025, 2.26% down from the prior year.
  • Total Liabilities for Q4 2025 was $17.3 million at Fulcrum Therapeutics, up from $16.5 million in the prior quarter.
  • The five-year high for Total Liabilities was $34.5 million in Q2 2022, with the low at $14.2 million in Q1 2025.
  • Average Total Liabilities over 5 years is $23.0 million, with a median of $23.4 million recorded in 2021.
  • The sharpest move saw Total Liabilities plummeted 33.02% in 2021, then increased 27.75% in 2022.
  • Over 5 years, Total Liabilities stood at $23.5 million in 2021, then increased by 18.25% to $27.7 million in 2022, then decreased by 18.89% to $22.5 million in 2023, then decreased by 21.41% to $17.7 million in 2024, then fell by 2.26% to $17.3 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $17.3 million, $16.5 million, and $14.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.